Introduction to CIN2 Management

Cervical intraepithelial neoplasia grade 2 (CIN2) often presents a significant clinical dilemma regarding whether to proceed with surgical treatment or observation. Recent research highlights the potential of CIN2 methylation biomarkers to predict lesion regression or progression accurately. This study utilized the Illumina 850k array to analyze DNA from serial liquid-based cytology cervical samples in young women undergoing active surveillance. Consequently, the findings offer a path toward more personalized gynecological care.

The Role of CIN2 Methylation Biomarkers

The study focused on identifying epigenetic changes that distinguish regressive lesions from those that persist or progress. Researchers discovered that methylation levels at specific genomic sites correlate strongly with clinical outcomes over 24 months. Specifically, three novel differentially-methylated sites were identified in the genes ALDH9A1, MED25, and TULP2. These markers provide a biological basis for distinguishing high-risk lesions from those suitable for monitoring. Furthermore, the study suggests these genes may play roles in the host response to viral mechanisms, particularly human papillomavirus (HPV).

Key Findings and Clinical Implications

The results revealed that ALDH9A1 methylation was significantly higher at baseline in women whose lesions did not regress. Conversely, lower MED25 methylation levels accurately predicted regression within the subsequent 12 months. In addition, TULP2 methylation increased over time in non-regressive cases compared to those that resolved. These CIN2 methylation biomarkers could help clinicians guide treatment decisions more effectively. However, while these results are promising, the authors emphasize that larger prospective studies are mandatory to validate these findings for routine clinical use.

Frequently Asked Questions

Which specific genes were identified as potential biomarkers?

The study identified ALDH9A1, MED25, and TULP2 as the primary genes where methylation levels significantly differed between regressive and non-regressive CIN2 lesions.

How can these biomarkers improve clinical practice?

By identifying which CIN2 lesions are likely to resolve spontaneously, these biomarkers can help clinicians safely recommend active surveillance and avoid unnecessary surgical interventions in low-risk patients.

What was the duration of the follow-up in this study?

The researchers monitored the participants over a 24-month period to distinguish between those with persistent or progressive disease and those who achieved regression.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Readers should consult with a qualified healthcare professional regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Ellis LB et al. Methylation biomarkers in non-regressive cervical intraepithelial neoplasia grade 2 lesions: an epigenome wide association study. Br J Cancer. 2026 Apr 11. doi: 10.1038/s41416-026-03391-4. PMID: 41965938.

2. Clarke MA et al. Molecular Biomarkers for the Detection of Cervical Neoplasia. Journal of Clinical Microbiology. 2023.

3. Kyrgiou M et al. Management of CIN2: Active surveillance or treatment? The Lancet Oncology. 2022.